Discounted Cash Flow Rating
Strong Buy
Return on Equity Rating
Neutral
Debt to Equity Rating
Neutral
Price to Earnings Rating
Strong Sell
Analyst Rating
Neutral
Simple Moving Average
Neutral
Exponential Moving Average
Neutral
Relative Strength Index
Neutral
Standard Deviation
Strong Buy
Williams %R
Strong Buy
Average Directional Index
Strong Sell
Insider Trading
Neutral
Wall Street Data Solutions Rating
Neutral
B
Renovaro Biosciences Inc. Common Stock (RENB)
Pharmaceutical Preparations
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
CENTURY CITY MEDICAL PLAZA, 2080 CENTURY CITY EAST
SUITE 906 LOS ANGELES, CA
Current Price
---.--
% Change Today
0.00%
Change Amt. Today
0.00
Active Status
Active
Listing Date
11/18/2014
Market Cap
95,317,731
Shares Outstanding
67,220,000
Weighted SO
67,224,089
Total Employees
N/A
Upcoming Earnings
N/A
Similar Tickers
Beta
0.5950
Last Div
0.0000
Range
0.42-5.25
Chg
-0.0331
Avg Vol
999230
Mkt Cap
95317731
Exch
NASDAQ
Country
US
Phone
305 918 1980
DCF Diff
0.7186
DCF
-0.0661
Div Yield
0.0000
P/S
0.0000
EV Multiple
-4.0215
P/FV
0.4120
Div Yield %
0.0000
P/E
-1.2879
PEG
-0.0192
Payout
0.0000
Current Ratio
0.0584
Quick Ratio
0.0584
Cash Ratio
0.0150
DSO
0.0000
DIO
0.0000
Op Cycle
0.0000
DPO
24563.5723
CCC
0.0000
Gross Margin
0.0000
Op Margin
0.0000
Pretax Margin
0.0000
Net Margin
0.0000
Eff Tax Rate
-0.0144
ROA
-0.2540
ROE
-0.7062
ROCE
-0.2784
NI/EBT
1.0000
EBT/EBIT
1.0121
EBIT/Rev
0.0000
Debt Ratio
0.0404
D/E
0.0508
LT Debt/Cap
0.0057
Total Debt/Cap
0.0484
Int Coverage
-51.3994
CF/Debt
-1.2620
Equity Multi
1.2591
Rec Turnover
0.0000
Pay Turnover
0.0149
Inv Turnover
0.0000
FA Turnover
0.0000
Asset Turnover
0.0000
OCF/Share
-0.1007
FCF/Share
-0.1012
Cash/Share
0.0029
OCF/Sales
0.0000
FCF/OCF
1.0049
CF Coverage
-1.2620
ST Coverage
-1.4231
CapEx Coverage
-204.0638
Div&CapEx Cov
-204.0638
P/BV
0.4120
P/B
0.4120
P/S
0.0000
P/E
-1.2879
P/FCF
-8.7670
P/OCF
-6.4195
P/CF
-6.4195
PEG
-0.0192
P/S
0.0000
EV Multiple
-4.0215
P/FV
0.4120
DPS
0.0000
Latest Headlines (EST)
No Headlines Found
Revenue Product Segmentation
Year | Purchases | Sales | Total Bought | Total Sold |
---|
Transaction Date | Name | Type Of Owner | Price | Securities Owned | Securities Transacted | Security Name | Transaction Type |
---|
Less Than 3 Months
0.00 Shares Bought (0 %)
0.00 Shares Sold (0%)
3 - 6 Months
0.00 Shares Bought (0 %)
0.00 Shares Sold (0%)
6 - 9 Months
0.00 Shares Bought (0 %)
0.00 Shares Sold (0%)
9 - 12 Months
0.00 Shares Bought (0 %)
0.00 Shares Sold (0 %)
Investor Name | Investment Discretion | Type of Security | Shares Owned | Avg Price Paid | Market Value | Change In Market Value | Change In Market Value (%) | Ownership | Weight |
---|
Date | Investors Holding | Closed Positions | Increased Positions | Reduced Positions | New Positions | Total Invested | Put/Call Ratio | Total Calls | Total Puts |
---|
Owner | Shares Owned |
---|
2022 | 2023 | 2024 | 1970 | 1970 | 1970 | 1970 | |
---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | ||||
Cost Of Revenue | 28.33K | ▼ 28.01K | ▲ 30.31K | ▼ | |||
Gross Profit | -28.33K | ▲ -28.01K | ▼ -30.31K | ▼ | |||
Gross Profit Ratio | 0.00 | 0.00 | 0.00 | ▼ | |||
Research And Development Expenses | 1.77M | ▼ 994.73K | ▲ 1.09M | ▼ | |||
General And Administrative Expenses | 0.00 | ▲ 2.95M | ▲ 7.65M | ▼ | |||
Selling And Marketing Expenses | 0.00 | 0.00 | 0.00 | ||||
Selling General And Administrative Expenses | 3.16M | ▼ 2.95M | ▲ 7.65M | ▼ | |||
Other Expenses | 0.00 | 0.00 | 0.00 | ||||
Operating Expenses | 4.93M | ▼ 3.97M | ▲ 8.77M | ▼ | |||
Cost And Expenses | 4.96M | ▼ 3.97M | ▲ 8.77M | ▼ | |||
Interest Income | 99.15K | ▼ 0.00 | 0.00 | ||||
Interest Expense | 94.52K | ▲ 262.26K | ▲ 320.07K | ▼ | |||
Depreciation And Amortization | 28.33K | ▼ 28.01K | ▲ 30.31K | ▼ | |||
Ebitda | -4.93M | ▲ -3.95M | ▼ -8.74M | ▼ | |||
Ebitda Ratio | 0.00 | 0.00 | 0.00 | ▼ | |||
Operating Income | -4.96M | ▼ -22.93M | ▲ -17.19M | ▼ | |||
Operating Income Ratio | 0.00 | 0.00 | 0.00 | ▼ | |||
Total Other Income Expenses Net | -85.28M | ▲ -18.96M | ▲ -7.93M | ▼ | |||
Income Before Tax | -90.24M | ▲ -23.20M | ▲ -17.02M | ▼ | |||
Income Before Tax Ratio | 0.00 | 0.00 | 0.00 | ▼ | |||
Income Tax Expense | -2.00 | ▲ 262.26K | ▲ 320.07K | ▼ | |||
Net Income | -90.24M | ▲ -23.20M | ▲ -17.02M | ▼ | |||
Net Income Ratio | 0.00 | 0.00 | 0.00 | ▼ | |||
Eps | -1.70 | ▲ -0.36 | ▲ -0.16 | ▼ | |||
Eps Diluted | -1.70 | ▲ -0.36 | ▲ -0.16 | ▼ | |||
Weighted Average Shs Out | 53.01M | ▲ 63.70M | ▲ 107.48M | ▼ | |||
Weighted Average Shs Out Dil | 53.01M | ▲ 63.70M | ▲ 107.48M | ▼ |